Creatine and Depression: What 2025 Research Reveals

Creatine is widely recognized as a performance supplement for athletes, but a fast-moving body of peer-reviewed research is examining a surprising second frontier: its potential role in reducing symptoms of depression. Systematic reviews published in 2025 and a 2026 meta-analysis of randomized controlled trials have added significant nuance to this question — and the findings are worth understanding carefully for anyone interested in the intersection of brain energy metabolism and mental health. This article unpacks the current evidence, the proposed mechanisms, the populations most likely to benefit, and the honest limitations of what we know so far.

The Brain Energy Deficit Hypothesis

Major depressive disorder (MDD) is not simply a serotonin deficiency. Neuroscientists have increasingly focused on a complementary mechanism: energy failure in prefrontal and limbic brain regions. Neurons are among the most metabolically demanding cells in the body, and disruptions in mitochondrial function and high-energy phosphate availability have been documented in MDD patients via phosphorus-31 magnetic resonance spectroscopy (31P-MRS).

Creatine sits at the center of cellular energy buffering. In the brain, creatine combines with inorganic phosphate via the enzyme creatine kinase to regenerate adenosine triphosphate (ATP) from adenosine diphosphate (ADP) — the phosphocreatine shuttle. This system is particularly critical during periods of high neuronal firing: exactly the kind of sustained metabolic activity required for mood regulation, executive function, and stress response. When brain creatine stores are depleted, this buffer loses capacity, and neuronal performance degrades under metabolic load.

Studies using 31P-MRS have found reduced phosphocreatine levels in the frontal lobes of patients with treatment-resistant depression, providing a mechanistic rationale for why creatine supplementation might help restore neuronal resilience. A 2024 review published in Nutrients (PMC11567172) mapped this framework comprehensively, tracing creatine's intersections with BDNF signaling, neuroplasticity, and serotonergic function.

What Clinical Trials Show: A 2025–2026 Evidence Update

The evidence base for creatine in depression has matured considerably in the past two years. A 2026 systematic review indexed in PubMed Central (PMC12823350) synthesized six articles from five randomized controlled trials (RCTs) involving 238 participants. Four RCTs focused on major depressive disorder; one examined bipolar depression. Key findings from that synthesis:

• Creatine supplementation consistently outperformed placebo on standardized depression rating scales across the majority of included trials.
• Pooled effect sizes for adjunctive creatine — added on top of antidepressants — were notably larger than for creatine as a standalone monotherapy.
• Mean participant age was 36 years; only 26% were male, indicating that most evidence to date comes from female participants with MDD.

A separate 2025 meta-analysis in the British Journal of Nutrition (Cambridge Core) found an average improvement of approximately 2.2 points on the 17-item Hamilton Depression Rating Scale (HDRS-17). The minimum clinically important difference on this scale is 3.0 points, so the average effect fell just below the threshold for clinical significance — a distinction worth noting for interpreting aggregate results versus individual trial outcomes.

The honest takeaway from the current literature: creatine is statistically significant in reducing depressive symptoms in most trials, but the average effect size at standard doses may be modest as a standalone intervention. The strongest signal comes from adjunctive use — pairing creatine with conventional antidepressants.

How Creatine May Amplify Antidepressants

The most compelling clinical data involves creatine as an add-on to selective serotonin reuptake inhibitors (SSRIs). A landmark RCT tested 5g/day creatine as an adjunct to escitalopram in women with MDD; creatine-augmented patients showed significantly greater response rates and achieved remission faster than the placebo + SSRI group, with response rates approximately 3.6 times higher by week eight.

The proposed mechanism is synergistic: SSRIs increase serotonin availability, while creatine supports the ATP-dependent processes that enable serotonin synthesis, vesicular packaging, and receptor signal transduction. A 2025 review in Frontiers in Psychiatry (Frontiers Psychiatry) elaborated on this interaction, noting that creatine also appears to modulate NMDA receptor function and support GABAergic balance — pathways relevant to both mood dysregulation and anxiety.

Creatine may also attenuate the neuroinflammatory component of depression. Elevated pro-inflammatory cytokines (including IL-6 and TNF-α) are documented in MDD and are known to suppress mitochondrial function. Creatine's role as an energy buffer may partially offset this suppression, preserving synaptic plasticity even under conditions of chronic low-grade neuroinflammation.

Dosing Protocols in the Research Literature

Understanding what doses the research actually used matters for interpreting the results properly. The following table summarizes the dosing landscape across published trials:

1. 2–5 g/day (standard range): Most RCTs have used this range as adjunctive therapy for 4–8 weeks. This aligns with maintenance dosing commonly used in sports science and is generally well tolerated.
2. 5–10 g/day (higher-dose protocols): Some trials exploring treatment-resistant or severe MDD used higher doses, particularly in cases where 31P-MRS confirmed reduced baseline brain creatine levels.
3. Duration: Trials with the most significant effects ran at least 6–8 weeks — consistent with the time needed for brain creatine concentrations to meaningfully elevate, given that the blood-brain barrier limits the rate of central creatine accumulation relative to muscle uptake.

All published RCTs have used creatine monohydrate, the most extensively studied form. A 5g dose reliably elevates plasma creatine and promotes tissue uptake over time. Brain accumulation is slower than in skeletal muscle, which may explain why mood-related effects tend to emerge over weeks rather than days.

Which Populations Show the Strongest Signal?

Not everyone is equally likely to respond to creatine for mood. Based on the current evidence, several subgroups stand out:

• Vegans and vegetarians: Dietary creatine comes almost entirely from meat and fish. Plant-based individuals have lower baseline muscle and brain creatine stores and may experience larger absolute gains from supplementation — and a correspondingly stronger effect on outcomes tied to creatine availability.
• Women with MDD: The RCT literature has disproportionately enrolled women. Some researchers hypothesize this reflects a genuine biological difference: estrogen modulates creatine transporter expression, and women may rely more heavily on dietary creatine to maintain brain creatine homeostasis.
• Patients with treatment-resistant depression: Where standard antidepressants have failed, the energy-deficit model may be a more prominent driver. Creatine augmentation in this population has shown promising results, though sample sizes remain small.
• Those with fatigue-prominent depression: Creatine's effects on both peripheral muscle energetics and central fatigue may make it particularly valuable for patients whose depression manifests with psychomotor slowing, brain fog, or prominent energy depletion.

Honest Limitations and What the Research Still Needs

The science is promising but not settled. Several limitations should temper overly strong conclusions from the current evidence base:

• Small aggregate sample sizes: The 2026 systematic review included only 238 participants across five trials. This limits statistical power and generalizability to broader MDD populations.
• Heterogeneous study populations: Trials vary in depression severity, medication background, and duration, making head-to-head comparisons difficult.
• Potential publication bias: Most published trials show positive results; null findings may be underreported, a common limitation in nutritional psychiatry research.
• Mechanistic confirmation gap: While the phosphocreatine/ATP model is biologically compelling, it is difficult to confirm that brain creatine levels actually increase meaningfully at doses used in most studies without concurrent 31P-MRS monitoring.
• Bipolar caution: The 2026 systematic review noted isolated reports of manic episodes in bipolar disorder patients supplementing with creatine, warranting caution in this population.

Active research directions include larger adequately powered RCTs, neuroimaging-stratified trials that enroll participants with confirmed brain energy deficits at baseline, and dose-escalation studies in treatment-resistant cohorts. The field is evolving rapidly, and several larger registered trials are expected to report results by 2027.

Key Takeaways for the Research-Minded Reader

Creatine supplementation is not a replacement for evidence-based mental health treatment, and nothing in this article should be read as clinical advice. What the current data do support is a plausible, mechanistically grounded rationale for creatine as an adjunctive intervention in MDD — particularly at 5g/day, alongside a prescribed antidepressant, over at least 6–8 weeks. For vegans, women, and those with fatigue-prominent or treatment-resistant depression, the biological rationale and clinical signal are both stronger than for the general population. Anyone considering creatine for mood support should discuss it with their prescribing physician before starting.